Alterations in the gut microbiome of children with severe ulcerative colitisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the fecal microbiome of children hospitalized with severe ulcerative colitis (UC) to healthy controls. They also compared children who responded to intravenous steroid therapy with those who did not.
How was it studied?
Fecal samples came from 27 hospitalized children with severe UC and 26 healthy age-matched controls in a prospective multicenter study. A custom microarray targeting 16S rRNA from 852 known gut bacterial phylospecies quantified relative signal strength for each species, then results were aggregated up through genus, family, order, class, and phylum.
What did they find?
Children with UC had far fewer detectable phylospecies than controls, 266 versus 758 on average, and a lower Shannon diversity index, 6.1 versus 6.49. At the phylum level, Firmicutes fell by about 5 percent of total signal while Proteobacteria rose by about 3.6 percent, and at the class level Clostridia dropped by over 8 percent with a rise in Gammaproteobacteria and Erysipelotrichi. Children who failed to respond to steroids had even lower richness than responders, 142 versus 338 phylospecies.
Why it matters
The findings suggest gut microbial richness and diversity decline with UC severity and may predict steroid response in children. This is described as the first large pediatric cohort study to characterize the gut microbiome in severe UC using this microarray approach.